The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering treatments for atrial fibrillation ("AF"), the most common cardiac arrhythmia, today announces enrolment of the first patients ...

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

Atlanta Workshop Players presents the Improv Mania Show! A family friendly night of comedy. on the Roswell Patch calendar ...

The new year means new TV series, but also some returning favorites, spinoffs and long-awaited series finales.

The Vocci AI Ring is an audio recorder on your finger. It can record interviews and highlight the important bits without ...